Successful treatment of mitomycin C-associated hemolytic uremic syndrome by plasmapheresis.
Therapeutic attempts have generally failed to reverse the rapid progression of renal failure after mitomycin C (MMC)-induced hemolytic uremic syndrome (HUS). A patient who developed HUS after MMC and who showed pathologic changes in the kidney consistent with thrombotic microangiopathy is reported. Treatment with plasmapheresis was followed by a favorable outcome and significant recovery of renal function. Accordingly, this therapeutic modality should be considered for patients with MMC-induced HUS.
Garibotto
G
G
Istituto Scientifico di Medicina Interna, University of Genoa, Italy.
Acquarone
N
N
Saffioti
S
S
Deferrari
G
G
Villaggio
B
B
Ferrario
F
F
D000328:Adult; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007668:Kidney / Q000473:pathology; D016685:Mitomycin; D008937:Mitomycins / Q000009:adverse effects*; D010956:Plasmapheresis
D008937:Mitomycins; D016685:Mitomycin